Key result
Ischemic-preconditioned MSC exosomes reduce cardiomyocyte apoptosis and fibrosis via miR-22 targeting Mecp2.
Mesenchymal stem cells (MSCs) have potential application for the treatment of ischemic heart diseases. Besides differentiation properties, MSCs protect ischemic cardiomyocytes by secretion of paracrine factors. In this study, we found exosomes enriched with miR-22 were secreted by MSCs following ischemic preconditioning (Exo(IPC)) and mobilized to cardiomyocytes where they reduced their apoptosis due to ischemia. Interestingly, by time-lapse imaging, we for the first time captured the dynamic shedding of miR-22 loaded exosomes from cytosol to extracellular space. Furthermore, the anti-apoptotic effect of miR-22 was mediated by direct targeting of methyl CpG binding protein 2 (Mecp2). In vivo data showed that delivery of Exo(IPC) significantly reduced cardiac fibrosis. Our data identified a significant benefit of Exo(IPC) for the treatment of cardiac diseases by targeting Mecp2 via miR-22.
No takes yet. Share an insight, caveat, or question.
Feng et al. (2014) studied Ischemic heart diseases. Exosomes from ischemic-preconditioned MSCs (Exo(IPC)) was evaluated on Cardiac fibrosis and cardiomyocyte apoptosis. Delivery of exosomes from ischemic-preconditioned mesenchymal stem cells significantly reduced cardiomyocyte apoptosis and cardiac fibrosis by targeting Mecp2 via miR-22.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: